Olanzapine pamoate monohydrate, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg, Zyprexa Relprevv®

Public summary document for Olanzapine pamoate monohydrate, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg, Zyprexa Relprevv®

Page last updated: 30 October 2009

PDF printable version for Olanzapine pamoate monohydrate, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg, Zyprexa Relprevv® (PDF 39 KB)

Public Summary Document

Product: Olanzapine pamoate monohydrate, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg, Zyprexa Relprevv®
Sponsor: Eli Lilly Australia Pty Ltd
Date of PBAC Consideration: July 2009

1. Purpose of Application

To request an Authority required listing for maintenance treatment of schizophrenia in adults stabilised during acute treatment with oral olanzapine.

2. Background

This formulation of olanzapine had not previously been considered by the PBAC.

At the March 1997 PBAC meeting, the PBAC recommended the listing of oral olanzapine as an Authority required PBS benefit for schizophrenia and related psychoses where other antipsychotic therapy has failed or is inappropriate.

At the July 2004 meeting the PBAC recommended an extension to the Authority required listing of olanzapine to include the maintenance treatment of bipolar 1 disorder based on acceptable cost-effectiveness compared with lithium.

3. Registration status

Olanzapine (as pamoate monohydrate) powder for injection vial with diluent vial was TGA registered on 3 March 2009 for the maintenance treatment of schizophrenia in adult patients sufficiently stabilised during acute treatment with oral olanzapine.

4. Listing Requested and PBAC’s View

Authority Required:
For maintenance treatment of schizophrenia in adult patients sufficiently stabilised during acute treatment with oral olanzapine.

For PBAC’s views see Recommendation and Reasons.

5. Clinical place for the proposed therapy

Olanzapine modified release injection would provide an alternative atypical antipsychotic depot injection option to risperidone for the treatment of schizophrenia.

6. Comparator

The submission nominated oral olanzapine as the clinical comparator. For pricing purposes the submission nominated risperidone modified release injection.

7. Clinical trials

The submission presented an indirect comparison of olanzapine long acting injection (OLAI) and risperidone long-acting injection (RLAI) with placebo as a common comparator, based on one trial of OLAI vs placebo (HGJZ) and one trial of RLAI vs placebo (Kane 2003).

Publication details of the trials are presented in the following table:

Trial ID Protocol / Publication title Date/citation
OLAI vs placebo
HGJZ Lauriello et al (2008) An 8-week, double-blind, randomised, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008; 69: 790-799.
RLAI vs placebo
Kane 2003 Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic. Am J Psychiatry 2003; 160: 1125-1132.
Lauriello et al 2005. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research 2005;72(2-3):249-58.


The submission presented one direct randomised comparative trial of OLAI vs oral olanzapine (Trial HGKA) in patients with schizophrenia previously stabilised on oral olanzapine as the pivotal evidence. The submission also presented one supportive trial of three doses of OLAI vs placebo (Trial HGJZ), and one supportive single arm, long term study of safety and efficacy (Study HGKB).

8. Results of Trials


OLAI vs RLAI
Both trial HGJZ and Kane 2003 investigated mean change from baseline to endpoint in Positive and Negative Symptom Score (PANSS) total score as a primary outcome. The results for each trial are presented in the table below.

Mean change from baseline of PANSS Total scores

Trial HGJZ N Baseline: mean (SE) Change: mean (SE) p value vs placebo: adjusted*
OLAI 210 mg /2 wks 106 99.6 (1.5) -22.5 (2.1) <0.001
OLAI 405 mg /4 wks 100 101.3 (1.4) -22.6 (2.2) <0.001
OLAI 300 mg /2 wks 98 102.6 (1.6) -26.3 (2.5) <0.001
Placebo 98 100.6 (1.7) -8.5 (2.3) -
Kane 2003 N Baseline: mean (SD) Change: mean (SD) p value vs placebo: adjusted †
RLAI 25 mg/ 2 wks 93 81.7 (12.5) -6.2 16.9 0.002
RLAI 50 mg /2 wks 98 82.3 (13.9) -8.5 16.9 <0.001
RLAI 75 mg/ 2 wks 87 80.1 (14.0) -7.4 16.9 <0.001
Placebo 92 82.0 (14.4) 2.6 16.9 -

PANSS = Positive and Negative Symptom Score; OLAI = olanzapine long acting injection;
RLAI = risperidone long acting injection; SE = standard error; SD = standard deviation; wks = weeks
* adjusted for base PANSS score
adjusted using Dunnett’s multiple comparisons method in Kane 2003

The submission did not provide an explanation of how the results of the differences in baseline to endpoint changes in PANSS Total scores for each group in either trial were combined for comparison with indirect analysis. It appeared that in each trial the three active treatment arms were pooled to give a weighted mean. The results of the indirect comparison are presented below.

Summary of results of indirect comparison of OLAI with RLAI via placebo

Outcome Risk estimate (95% CI) p value
PANSS total score weighted mean difference -5.1 (-11.8, 1.7) 0.14
Response 20%* Odds ratio 0.8 (0.4, 1.7) 0.55
Anticholinergic use Odds ratio 0.9 (0.3, 2.5) 0.78

PANSS = Positive and Negative Symptom Scale.
* number of patients having a response of at least 20% improvement in PANSS Total score.

The indirect analysis of OLAI and RLAI showed no statistically significant differences in PANSS Total score, the number of patients with at least a 20% improvement in PANSS Total score, or use of anticholinergics (used as a proxy of extrapyramidal adverse events). However, the different durations of the trials and difference in severity of patients in each trial made these results difficult to interpret.

OLAI vs ORAL OLANZAPINE
The primary outcome was the difference in exacerbation rates of schizophrenia between the pooled 150 mg/2 weeks and 300 mg/2 weeks doses compared with oral olanzapine (10 mg, 15 mg or 20 mg/day pooled) in Trial HGKA. The specified non-inferiority rate was a delta of 0.20.

The differences in exacerbation-free rates (for schizophrenia) were within the specified noninferiority margin for the primary analysis and the post-hoc subgroup analysis. However, there was a statistically significant difference between the 150 mg/2 weeks dose compared with oral olanzapine in discontinuations due to relapse and risk of exacerbation of schizophrenia. The submission stated that the dose of 150 mg/2 weeks will not be marketed in Australia, but the 300 mg dose given every 4 weeks was equivalent. No clinical data were provided for a dose of 300 mg/4 weeks.

With respect to adverse events, OLAI appeared to have a similar adverse events profile as oral olanzapine with the exception of post injection syndrome (inadvertent intravascular injection) which resulted in a clinical picture of olanzapine overdose. There was a statistically significantly higher number of treatment emergent and serious adverse events reported for the 150 mg/2 week dose group compared with oral olanzapine in Trial HGKA. However, as these events included “schizophrenia” and other symptoms and signs related to psychosis (e.g. delusions, paranoia), these appear to be related to the efficacy in this group on the underlying condition, rather than drug related adverse events.

A risk management plan was provided for adverse events associated with the administration of OLAI, including postmarketing surveillance and an observational study of post-injection syndrome, provision of appropriate labelling with descriptions of the clinical manifestations, the type and duration of observations to monitor patients for post-injection syndrome, management if post injection syndrome should occur, and provision of appropriate training for health professionals who administer OLAI.

9. Clinical Claim

The submission claimed that olanzapine long acting injection was no worse than risperidone long acting injection in terms of efficacy. The submission did not make a formal claim with respect to the comparative safety of OLAI and RLAI.

For PBAC’s views see Recommendation and Reasons.

10. Economic Analysis

In summary, the submission requested a higher price for OLAI in comparison with oral olanzapine by using RLAI as the main comparator, which had previously been accepted by the PBAC as being superior to oral risperidone.

Cost-minimisation against RLAI with the stated objective of pricing OLAI “such that the relative price of OLAI to oral olanzapine is no greater than the relative price of RLAI to oral risperidone in absolute terms.”

Based on equating oral risperidone 4 mg/day with oral olanzapine 15 mg/day, the submission calculated the equi-effective doses for RLAI and OLAI as presented in the table below:

Equi-effective doses for RLAI and OLAI as presented in the submission

RLAI Oral risperidone Oral olanzapine OLAI
25 mg / 2 weeks NS NS No equivalent
37.5 mg / 2 weeks NS 10 mg / day 300 mg / 4 weeks
50 mg / 2 weeks 4 mg / day 15 mg / day 210 mg / 2 weeks, 405 mg / 4 weeks.
No equivalent NS 20 mg / day 300 mg / 2 wks

NS = not stated

During the evaluation it was noted that the Davis and Chen (2004) study reported that the near-maximal effective dose (ED95) of risperidone was 4 mg per day, and the ED95 of olanzapine was greater than 16 mg per day, and may in fact be as high as 20 mg per day or more. They also found that the median effective dose (ED50) of risperidone was 2mg per day, and of olanzapine was 9 mg per day. Thus, the PBAC was advised it may be more accurate to equate the 4 mg dose of risperidone to the 20 mg dose of olanzapine. Based on equating oral risperidone 4 mg/day with oral olanzapine 20 mg/day, the equi-effective doses for RLAI and OLAI were re-calculated during the evaluation as presented in the table below:

Recalculated equi-effective doses for RLAI and OLAI

RLAI Oral risperidone Oral olanzapine OLAI
25mg / 2 weeks < 2 mg / day 10 mg / day 300 mg / 4 weeks
25 to 37.5 mg / 2 weeks 2 to 4 mg / day 15 mg / day 210 mg / 2 weeks or 405 mg / 4 weeks
37.5 to 50 mg / 2 weeks 4 mg / day 20 mg / day 300 mg / 2 wks

Source: Antipsychotic Drug Guidelines 2006, Western Australian Psychotropic Drugs Committee, Davis and Chen 2004, Citrome and Volavka 2002

The cost-minimisation analysis presented in the submission was based on the expected daily treatment cost associated with OLAI and RLAI.

The submission derived a saving per patient per year for OLAI treatment compared with RLAI. Using the alternative dose equivalence derived during the evaluation, treatment with OLAI resulted in an additional cost of approximately per patient per year compared with RLAI. Both of these costs were calculated without including any costs of administration of OLAI, including monitoring patients for 3 hours in case of the occurrence of post injection syndrome. The cost-minimisation analysis was sensitive to the assumed equi-effective doses and the proportions of different doses of OLAI and RLAI used in the population.

11. Estimated PBS usage and Financial Implications

The likely number of patients per year was less than 10,000 patients per year The financial cost per year to the PBS was less than $10 million per year.

12. Recommendation and Reasons

The PBAC recommended the listing of olanzapine pamoate monohydrate modified release (MR) injection as an Authority required (Streamlined) benefit for the treatment of schizophrenia. The PBAC recommended that, consistent with its recommendation for modified release risperidone injection, the relative price advantage for olanzapine pamoate monohydrate modified release injection over the monthly treatment cost of oral olanzapine should be the same as haloperidol decanoate intramuscular injection had over oral haloperidol (1:1.79), with a reduction to off-set the cost of monitoring olanzapine for post injection syndrome. The equi-effective doses are 10 mg daily oral olanzapine to 300 mg every four weeks olanzapine MR injection, 15 mg daily oral olanzapine to 210 mg every two weeks or 405 mg every four weeks olanzapine MR injection and 20 mg daily oral olanzapine to 300 mg every two weeks olanzapine MR injection.

The PBAC considered the method used in the submission to calculate equi-effective doses against modified release risperidone injection was complex and highly uncertain and hence did not accept the pricing proposed in the submission based on these calculations or that proposed during evaluation.

The PBAC considered the evidence presented (trial HGKA) supports the non-inferiority of olanzapine MR injection to oral olanzapine. The indirect comparison of trial HGJZ and Kane 2003 also suggests non-inferiority of olanzapine MR injection to risperidone MR injection, however this conclusion is somewhat uncertain due to the indirect nature of the analysis and differences in the duration of the trials and the severity of the trial patients. The PBAC considered the evidence presented indicates that olanzapine MR injection has a similar side effect profile to oral olanzapine with the exception of post injection syndrome. The PBAC was concerned about the potential for post injection syndrome to occur and hence recommended adding a CAUTION to the restriction highlighting the Product Information recommendation to monitor the patient for the signs and symptoms of post injection syndrome for at least three hours after administration.

The PBAC considered the listing will provide prescribers with an additional long acting atypical antipsychotic treatment option for schizophrenia. The PBAC requested that the National Prescribing Service consider providing education on the use of olanzapine modified release injection in the treatment of schizophrenia and the importance of monitoring for the signs and symptoms of post injection syndrome for at least three hours after administration of each injection.

Recommendation
OLANZAPINE PAMOATE MONOHYDRATE, powder for injection with diluent vial, 210 mg, 300 mg and 405 mg

Restriction:
CAUTION:
Monitor for post-injection syndrome for at least three hours after each injection.

Authority Required (STREAMLINED)

Schizophrenia in a patient who can be stabilised with oral olanzapine.

NOTE:

No applications for increased maximum quantities and/or repeats will be authorised.


Max qty: 2 (210 mg and 300 mg), 1 (405 mg)
Repeats: 5 (all strengths)

13. Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

14. Sponsor’s Comment

The sponsor welcomes the decision by the PBAC to provide an alternative long acting depot formulation for the treatment of schizophrenia

.